The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1063
October 8, 1999
View Complete Issue         Table of Contents 2019 
Two Neuraminidase Inhibitors for Treatment of Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Neuraminidase Inhibitors for Treatment of Influenza
October 8, 1999 (Issue: 1063)
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Neuraminidase Inhibitors for Treatment of Influenza
Article code: 1063a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.